10 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Early-stage classical Hodgkin lymphoma is Hodgkin lymphoma confined to lymph node regions on one side of the diaphragm, one of the most curable cancers, with most patients cured by a short course of ABVD chemotherapy with or without radiotherapy to the involved nodes. Because patients are young, trials now use PET scans after two cycles to give as little treatment as safely possible.
Classical Hodgkin lymphoma is a B-cell lymphoma in which the malignant Hodgkin and Reed-Sternberg cells, CD30 and CD15 positive and usually CD20 negative, are outnumbered by a reactive inflammatory background; nodular sclerosis is the commonest subtype in young adults, and PD-L1 amplification at 9p24.1 is near universal. Stage I and II disease is divided into favourable and unfavourable groups by the presence of bulky disease, raised erythrocyte sedimentation rate, B symptoms, three or more nodal sites or extranodal extension, definitions that differ slightly between the German Hodgkin Study Group (GHSG) and the EORTC. Radiotherapy alone cured most patients with early disease from the 1960s, but the second cancers and heart disease it caused decades later drove the shift to combined chemotherapy with smaller radiation fields and lower doses.
GHSG HD10 (New England Journal of Medicine 2010) showed that two cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) with 20 Gy of involved-field radiotherapy was enough for favourable disease, and HD11 and HD14 defined four cycles of chemotherapy (or two escalated BEACOPP plus two ABVD) with 30 Gy for unfavourable disease. Interim PET then became the tool for de-escalation: three trials in favourable disease, RAPID (New England Journal of Medicine 2015), EORTC H10 and GHSG HD16, found that omitting radiotherapy in patients who were PET-negative after two or three ABVD cycles lowered progression-free survival (90.8% against 94.6% at three years in RAPID, 87.1% against 99% at five years in H10, 86.1% against 93.4% at five years in HD16), and none showed non-inferiority, so the 2026 EHA guideline keeps two cycles of ABVD with 20 Gy as the standard and says omission can be discussed with patients in complete metabolic remission. In unfavourable disease, HD17 showed that radiotherapy can be omitted after a negative PET following two escalated BEACOPP and two ABVD cycles (five-year progression-free survival 95.1% against 97.3%, non-inferior). Radiotherapy, where given, uses involved-site fields with modern conformal or proton techniques that spare the heart and breasts. Brentuximab vedotin and PD-1 antibodies, established in advanced disease, are moving into early-stage trials: the Children's Oncology Group AHOD2131 trial gives every patient aged 5 to 60 with stage I or II disease two cycles of ABVD and then compares brentuximab vedotin plus nivolumab with further standard chemotherapy, and the GHSG NIVAHL phase 2 trial tested nivolumab with AVD. Fertility preservation, cardiac protection and lifelong survivorship care, including breast screening for women irradiated young, are part of standard management.
| Setting | Approach | Guideline |
|---|---|---|
| Staging | FDG-PET/CT with Lugano staging; bone marrow biopsy no longer needed when PET is used; fertility counselling and cardiac baseline. | not mapped |
| Early favourable disease | Two cycles of ABVD with 20 Gy involved-site radiotherapy (HD10); or, after discussion, chemotherapy alone for patients who are PET-negative (three ABVD in RAPID), accepting more relapses: progression-free survival was 4 to 12 points lower without radiotherapy in RAPID, HD16 and H10. | not mapped |
| Early unfavourable disease | Four cycles of ABVD (or two escalated BEACOPP plus two ABVD) with 30 Gy involved-site radiotherapy; after two escalated BEACOPP plus two ABVD, radiotherapy can be omitted in PET-negative patients (HD17). | not mapped |
| Children and adolescents | Response-adapted Children's Oncology Group regimens with radiotherapy for slow responders; AHOD2131 tests brentuximab vedotin with nivolumab. | not mapped |
| Survivorship | Cardiac surveillance, yearly breast screening from eight years after chest radiotherapy (not before age 25) in women irradiated before 36, thyroid checks and second-cancer awareness for life. | not mapped |
| Early favourable Hodgkin lymphoma: two cycles of ABVD and 20 Gy, and the argument about leaving the radiotherapy out | GHSG HD10 established the smallest combined-modality treatment that works: two cycles of ABVD followed by 20 Gy involved-field radiotherapy was as effective as the larger treatments. Five-year freedom from treatment failure was 91.1 per cent with two cycles against 93.0 per cent with four, not a significant difference, with no significant difference in overall survival and none between 20 Gy and 30 Gy, and adverse events were commonest with four cycles and 30 Gy. Four visits of chemotherapy and a fortnight of radiotherapy cure the great majority. Whether the radiotherapy can be dropped in patients whose PET is negative has been asked twice, and both answers were the same. HD16 randomised 1,150 patients: among 628 who were PET-negative after two cycles, five-year progression-free survival was 93.4 per cent with combined-modality treatment against 86.1 per cent with ABVD alone (difference 7.3 percentage points, hazard ratio 1.78), with five-year overall survival of 98.1 and 98.4 per cent. RAPID randomised patients whose PET was negative after three cycles and found three-year progression-free survival of 94.6 per cent with radiotherapy against 90.8 per cent without, with no difference in overall survival and non-inferiority not formally shown. So omitting radiotherapy costs a few percentage points of disease control and costs nothing in survival, while avoiding a field over the heart, breasts, thyroid and lungs in a person who will live another fifty years. It is a genuine choice and it is made differently by different patients and different countries. A Deauville score of 4 on the interim PET predicts a much higher risk of failure than a score of 3, and those patients keep the radiotherapy. | NCCN Category 1 |
| Early unfavourable Hodgkin lymphoma: more chemotherapy, and PET-guided intensification | Early-stage disease with risk factors (a large mediastinal mass, extranodal involvement, a raised erythrocyte sedimentation rate, three or four or more nodal areas, or age 50 or over depending on the criteria used) is treated with four cycles of chemotherapy and involved-site radiotherapy at 30 Gy, or with more intensive chemotherapy in place of some of it. EORTC/LYSA/FIL H10 randomised 1,950 patients and settled the PET-adapted question in both directions. In the 18.8 per cent whose PET after two cycles of ABVD was positive, switching to two cycles of escalated BEACOPP with involved-node radiotherapy raised five-year progression-free survival from 77.4 to 90.6 per cent (hazard ratio 0.42). At the preplanned ten-year analysis the difference was no longer statistically significant (hazard ratio 0.67, 95 per cent confidence interval 0.37 to 1.20). In PET-negative patients, non-inferiority of ABVD alone could not be demonstrated in either the favourable group (99.0 against 87.1 per cent for combined-modality treatment) or the unfavourable group (92.1 against 89.6 per cent), so omitting radiotherapy again costs disease control. Brentuximab vedotin with AVD is an option for unfavourable early-stage disease in some guidelines, and AHOD2131, an international trial in patients aged 5 to 60 with stage I to II disease, is testing response-adapted brentuximab vedotin with nivolumab against standard therapy with or without radiation. That trial is the one most likely to change this row next. | NCCN Category 1 |
| Children, adolescents and young adults with early-stage Hodgkin lymphoma | Paediatric protocols differ from adult ones in two ways that matter: they use response-adapted designs to remove radiotherapy from as many children as possible, and they avoid or limit the agents with the worst late effects in a growing body, particularly alkylating agents and chest radiotherapy. Children's Oncology Group and EuroNet protocols give a short course of multi-agent chemotherapy, assess response with PET after two cycles, and give involved-site radiotherapy only to sites that have not responded adequately. The aim is to cure more than 95 per cent of children with the smallest cumulative dose of anthracycline, alkylator and radiation they can be cured with. AHOD1331 showed the direction of travel in high-risk paediatric disease: replacing bleomycin with brentuximab vedotin gave three-year event-free survival of 92.1 per cent against 82.5 per cent (hazard ratio 0.41), with three-year overall survival of 99.3 against 98.5 per cent, similar toxicity and a similar proportion receiving radiotherapy (53.4 against 56.8 per cent). AHOD2131 is now testing brentuximab vedotin with nivolumab against standard therapy in early-stage disease across the ages of 5 to 60, which is unusual and deliberate: adolescents and young adults have historically fallen between paediatric and adult trials and done worse for it. Growth, fertility, thyroid function, cardiac function and psychological support are part of the treatment plan from the first appointment, not the end of it. | not mapped |